Total Payments
$25,162
2024 Payments
$2,186
Companies
8
Transactions
57
Medicare Patients
392
Medicare Billing
$73,150
Payment Breakdown by Category
Consulting$21,061 (83.7%)
Food & Beverage$2,905 (11.5%)
Travel$1,088 (4.3%)
Research$108.81 (0.4%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $21,061 | 11 | 83.7% |
| Food and Beverage | $2,905 | 41 | 11.5% |
| Travel and Lodging | $1,088 | 4 | 4.3% |
| Unspecified | $108.81 | 1 | 0.4% |
Payments by Type
General
$25,053
56 transactions
Research
$108.81
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Kite Pharma, Inc. | $11,549 | 28 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $6,158 | 15 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $2,768 | 1 | $0 (2022) |
| Takeda Pharmaceuticals U.S.A., Inc. | $2,640 | 1 | $0 (2020) |
| Novartis Pharma AG | $1,436 | 2 | $0 (2024) |
| Gilead Sciences, Inc. | $419.77 | 8 | $0 (2024) |
| Janssen Biotech, Inc. | $128.35 | 1 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $62.82 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,186 | 10 | Novartis Pharma AG ($1,313) |
| 2023 | $3,145 | 9 | Kite Pharma, Inc. ($2,632) |
| 2022 | $3,425 | 11 | E.R. Squibb & Sons, L.L.C. ($2,768) |
| 2021 | $3,780 | 1 | Kite Pharma, Inc. ($3,780) |
| 2020 | $7,430 | 4 | Novartis Pharmaceuticals Corporation ($3,290) |
| 2019 | $4,247 | 19 | Kite Pharma, Inc. ($2,160) |
| 2018 | $949.36 | 3 | Kite Pharma, Inc. ($935.69) |
All Payment Transactions
57 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $145.51 | General |
| 10/05/2024 | SANOFI-AVENTIS U.S. LLC | REZUROCK (Drug) | Food and Beverage | In-kind items and services | $62.82 | General |
| Category: Oncology | ||||||
| 09/26/2024 | Gilead Sciences, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $99.15 | General |
| Category: CELLT | ||||||
| 09/25/2024 | Gilead Sciences, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $9.68 | General |
| Category: CELLT | ||||||
| 09/24/2024 | Gilead Sciences, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $45.33 | General |
| Category: CELLT | ||||||
| 06/25/2024 | Janssen Biotech, Inc. | — | Food and Beverage | In-kind items and services | $128.35 | General |
| 05/16/2024 | Novartis Pharmaceuticals Corporation | KYMRIAH (Drug) | Food and Beverage | In-kind items and services | $130.72 | General |
| Category: Oncology | ||||||
| 05/16/2024 | Novartis Pharmaceuticals Corporation | KYMRIAH (Drug) | Food and Beverage | In-kind items and services | $126.78 | General |
| Category: Oncology | ||||||
| 03/06/2024 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 01/24/2024 | Novartis Pharma AG | KYMRIAH (Biological) | Consulting Fee | Cash or cash equivalent | $1,312.50 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2023 | Kite Pharma, Inc. | Tecartus (Drug) | Consulting Fee | Cash or cash equivalent | $2,390.00 | General |
| Category: CELLT | ||||||
| 12/11/2023 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $124.96 | General |
| Category: CELLT | ||||||
| 12/10/2023 | Novartis Pharma AG | KYMRIAH (Biological) | Food and Beverage | In-kind items and services | $123.51 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2023 | Gilead Sciences, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $59.76 | General |
| Category: CELLT | ||||||
| 12/09/2023 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $117.31 | General |
| 10/02/2023 | Novartis Pharmaceuticals Corporation | KYMRIAH (Drug) | Food and Beverage | In-kind items and services | $104.00 | General |
| Category: Oncology | ||||||
| 08/09/2023 | Novartis Pharmaceuticals Corporation | KYMRIAH (Drug) | Food and Beverage | In-kind items and services | $124.75 | General |
| Category: Oncology | ||||||
| 08/09/2023 | Novartis Pharmaceuticals Corporation | KYMRIAH (Drug) | Food and Beverage | In-kind items and services | $66.43 | General |
| Category: Oncology | ||||||
| 02/17/2023 | Novartis Pharmaceuticals Corporation | KYMRIAH (Drug) | Food and Beverage | In-kind items and services | $34.18 | General |
| Category: Oncology | ||||||
| 12/11/2022 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $23.48 | General |
| Category: CELLT | ||||||
| 12/10/2022 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $123.10 | General |
| 10/19/2022 | Novartis Pharmaceuticals Corporation | KYMRIAH (Biological) | Food and Beverage | In-kind items and services | $96.50 | General |
| Category: ONCOLOGY | ||||||
| 10/19/2022 | Novartis Pharmaceuticals Corporation | KYMRIAH (Biological) | Food and Beverage | In-kind items and services | $18.25 | General |
| Category: ONCOLOGY | ||||||
| 09/22/2022 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $13.17 | General |
| 09/21/2022 | Gilead Sciences, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $101.42 | General |
| Category: CELLT | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (ZUMA 2) | Kite Pharma, Inc. | $108.81 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 95 | 164 | $53,806 | $15,295 |
| 2022 | 2 | 89 | 175 | $57,561 | $16,543 |
| 2021 | 3 | 98 | 205 | $69,055 | $20,378 |
| 2020 | 4 | 110 | 250 | $51,646 | $20,934 |
Total Patients
392
Total Services
794
Medicare Billing
$73,150
Procedure Codes
11
All Medicare Procedures & Services
11 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 55 | 99 | $28,061 | $7,790 | 27.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 40 | 65 | $25,745 | $7,504 | 29.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 38 | 78 | $30,498 | $9,138 | 30.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 51 | 97 | $27,063 | $7,404 | 27.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 41 | 100 | $37,340 | $11,490 | 30.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 46 | 94 | $25,470 | $7,353 | 28.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 11 | 11 | $6,245 | $1,535 | 24.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 41 | 95 | $20,747 | $8,625 | 41.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 15 | 68 | $14,893 | $5,790 | 38.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 39 | 72 | $11,131 | $4,423 | 39.7% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 15 | 15 | $4,875 | $2,097 | 43.0% |
About Dr. Michael Jain, MD
Dr. Michael Jain, MD is a Hematology healthcare provider based in Tampa, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/01/2017. The National Provider Identifier (NPI) number assigned to this provider is 1982139655.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Jain, MD has received a total of $25,162 in payments from pharmaceutical and medical device companies, with $2,186 received in 2024. These payments were reported across 57 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($21,061).
As a Medicare-enrolled provider, Jain has provided services to 392 Medicare beneficiaries, totaling 794 services with total Medicare billing of $73,150. Data is available for 4 years (2020–2023), covering 11 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Location Tampa, FL
- Active Since 05/01/2017
- Last Updated 05/01/2017
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1982139655
Products in Payments
- KYMRIAH (Biological) $7,008
- Yescarta (Drug) $4,038
- Tecartus (Drug) $2,390
- KYMRIAH (Drug) $586.86
- REZUROCK (Drug) $62.82
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology Doctors in Tampa
Rami Komrokji, M.d, M.D
Hematology — Payments: $850,782
Hematology $850,782
Dr. Julia Cogburn, M.d, M.D
Hematology — Payments: $133,076
Hematology $133,076
Dr. Robert Weaver, Md, MD
Hematology — Payments: $110,649
Hematology $110,649
Alan List, Md, MD
Hematology — Payments: $94,305
Hematology $94,305
Dr. David Wright, Md, MD
Hematology — Payments: $82,377
Hematology $82,377
Lubomir Sokol, Md, MD
Hematology — Payments: $27,903
Hematology $27,903